INFLECTIS BIOSCIENCE
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 2013-01-01
- Employees
- -
- Market Cap
- -
Clinical Trials
3
Active:1
Completed:2
Trial Phases
2 Phases
Phase 1:2
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (66.7%)Phase 2
1 (33.3%)Treatment Combining Riluzole and IFB-088 in Bulbar Amyotrophic Lateral Sclerosis (TRIALS Protocol)
Phase 2
Completed
- Conditions
- Amyotrophic Lateral SclerosisALS
- Interventions
- First Posted Date
- 2022-08-19
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- InFlectis BioScience
- Target Recruit Count
- 51
- Registration Number
- NCT05508074
- Locations
- 🇫🇷
Hôpital Neurologique Pierre Wertheimer, Bron, France
🇫🇷APHM Hôpital La Timone Adultes SCE Maladies Neuromusculaires / SLA, Marseille Cedex 05, France
🇫🇷CHU de Nantes - Hôpital Laennec, Nantes, France
A Combined SAD and MAD Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of IFB-088
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: IFB-088 (2.5-60.0mg) oral capsuleDrug: Placebo (2.5-60.mg) oral capsuleDrug: IFB-088 (15.0-50.0mg) oral capsuleDrug: Placebo oral (15.0-50.0mg) capsule
- First Posted Date
- 2018-08-01
- Last Posted Date
- 2022-01-26
- Lead Sponsor
- InFlectis BioScience
- Target Recruit Count
- 72
- Registration Number
- NCT03610334
- Locations
- 🇫🇷
Eurofins|Optimed, Gières, France
🇫🇷Centre d'Investigation Clinique - Centre de Pharmacologie Clinique et d'Evaluations Thérapeutiques (CIC-CPCET), Marseille, France
News
IFB-088 Shows Promise in Phase 2 Trial for Bulbar-Onset ALS, Demonstrating Slower Disease Progression
Phase 2 clinical trial demonstrates IFB-088 (icerguastat) meets primary safety endpoint and shows significant reduction in disease progression for bulbar-onset ALS patients.